Get the latest news on PhotoCure stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on PHCUF performance

Latest PhotoCure Stock News | OTC:PHCUF | Benzinga

PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, and the United States.

PhotoCure ASA

Press Releases

European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care

Earnings

Small Cap

Photocure ASA: Annual Report 2023

Photocure ASA - Notice of the Annual General Meeting 23 May 2024

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Photocure ASA: Results for the first quarter of 2024

Photocure ASA - Annual general meeting held

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

Photocure ASA: Results for the second quarter of 2024

PHCUF

PhotoCure

Comments

PhotoCure Stock News

News

Latest PhotoCure Stock News | OTC:PHCUF | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga